Related Experiment Videos

Biological role of HGF/MET pathway in renal cell carcinoma

S Horie1, S Aruga, H Kawamata

  • 1Department of Urology, University of Tokyo, National Cancer Center Hospital, Japan.

The Journal of Urology
|February 18, 1999
PubMed
Abstract

Insights

Hepatocyte growth factor (HGF) and its receptor MET are expressed in renal cell carcinoma (RCC). HGF enhances RCC cell invasion and inhibits apoptosis, suggesting a role in cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Hepatocyte growth factor (HGF) and its receptor MET are implicated in the progression of various cancers.
  • Their specific role in renal cell carcinoma (RCC) warrants further investigation.

Purpose of the Study:

  • To evaluate the gene expression of HGF and MET in RCC tissues.
  • To examine the impact of HGF on the biological activities of cultured RCC cells.

Main Methods:

  • Quantitative competitive RT-PCR was used to assess HGF and MET gene expression in 27 primary RCC tumors.
  • HGF cDNA was transfected into Caki-1 RCC cells to study effects on chemoinvasion, matrix metalloproteinase-9 (MMP-9) expression, and Fas-induced apoptosis.

Main Results:

  • HGF and MET mRNA were detected in all RCC specimens, with HGF mRNA levels correlating with tumor volume.
  • Overexpression of HGF in Caki-1 cells led to increased invasiveness and MMP-9 activity.
  • HGF overexpression reduced sensitivity to Fas-induced apoptosis, an effect reversed by anti-HGF antibody.

Conclusions:

  • HGF enhances the invasive potential of RCC cells and inhibits Fas-induced apoptosis in vitro.
  • Both HGF and MET are expressed in RCC tissues.
  • The HGF/MET pathway is likely a significant factor in RCC progression.

Related Concept Videos